Taking NAD+ Directly vs NMN and NR: Why the Precursors Win Every Time

← Back to articles

As NAD+ (nicotinamide adenine dinucleotide) has gone mainstream in longevity talk, a predictable thing has happened: companies are now selling NAD+ itself in capsules, sublingual lozenges, and patches. The pitch — take the exact molecule you want to raise, skip the precursor — sounds obvious. In reality, oral NAD+ is the one form of the molecule you specifically should not buy.

The molecular-size problem

NAD+ is a large, charged dinucleotide (molecular weight about 663 daltons), well above the ~500-dalton ceiling that small molecules typically need to slip across the gut wall on their own. In the gut and bloodstream, NAD+ is rapidly chopped up by enzymes (CD38, CD73, and others) into smaller pieces — mainly nicotinamide (NAM) and ribose. The practical result: pay for NAD+, absorb nicotinamide at about the same efficiency as taking nicotinamide directly, at a much higher cost (Rajman 2018; PMID 29514064; DOI 10.1016/j.cmet.2018.02.011).

Why the precursors actually work

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are smaller and use dedicated cellular doorways. NR is taken into cells through nucleoside transporters (ENT1, ENT2) and quickly phosphorylated to NMN inside the cell. NMN is then turned into NAD+ by enzymes called NMNATs. The first dose-finding trial in humans showed that single oral doses of 100, 300, or 1,000 mg of NR produced clear, dose-dependent rises in blood NAD+ metabolites (Trammell 2016; PMID 27721479; DOI 10.1038/ncomms12948). NMN has its own transporter story (Slc12a8 was proposed in some tissues but is contested in others) and also produces measurable NAD+ increases at practical oral doses (Yoshino 2018; PMID 29249689; DOI 10.1016/j.cmet.2017.11.002). Direct oral NAD+ has not matched these results.

What about IV and sublingual NAD+?

IV NAD+ bypasses the gut problem and does raise blood NAD+, but the rise is rapid, short-lived, and the cost per session is high; long-term outcome data are sparse. Sublingual NAD+ lozenges sit between the two: they avoid the stomach but still meet the same plasma- and tissue-degrading enzymes. Published pharmacokinetic data for sublingual NAD+ are weaker than for sublingual NMN.

Cost per real NAD+ rise

A 300 mg daily dose of oral NAD+ typically retails for about $2–4/day; the same dose of NMN or NR, which actually moves NAD+ metabolites in blood, runs roughly $1–2/day. The premium pricing of direct NAD+ products is not matched by performance.

Practical recommendation

If your goal is to raise NAD+ with an oral supplement, choose NR or NMN at 250–1,000 mg/day. Direct oral NAD+ is not a useful upgrade. Reserve IV NAD+ for specific clinical contexts (under medical supervision) where the cost and rapid clearance are acceptable trade-offs.